Benralizumab phase III trials show positive results in severe asthma
- Details
- Category: AstraZeneca
Results from pivotal Phase III trials presented at the European Respiratory Society (ERS) International Congress demonstrated that adding benralizumab to standard-of-care medicine significantly reduced exacerbations and improved lung function and asthma symptoms in severe asthma patients with an eosinophilic phenotype, as indicated by the presence of eosinophils in their blood.
Amgen obtains global development and commercial rights from Boehringer Ingelheim for investigational BiTE® immuno-oncology drug for multiple myeloma
- Details
- Category: Amgen
Amgen (NASDAQ:AMGN) and Boehringer Ingelheim today announced that Amgen has acquired global development and commercial rights from Boehringer Ingelheim for BI 836908 (AMG 420), a bispecific T cell engager (BiTE®) that targets B-cell maturation antigen (BCMA), a potential target for multiple myeloma.
Saniona and Boehringer Ingelheim sign collaboration agreement in schizophrenia
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim, one of the world's 20 leading pharmaceutical companies, and Saniona, a leading biotech company in the field of ion channel drug discovery, have entered into a research collaboration with the objective to discover and develop novel compounds for the treatment of schizophrenia.
Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp
- Details
- Category: Novartis
Novartis today opened the 13th International Biotechnology Leadership Camp (BioCamp). Over the course of three days more than 60 selected students from international universities will discuss and explore with biotechnology and business experts how patients around the world can benefit from innovative technologies.
Pfizer to acquire small molecule anti-infective business from AstraZeneca
- Details
- Category: Pfizer
Pfizer Inc. (NYSE:PFE) today announced that it has entered into an agreement with AstraZeneca to acquire the development and commercialization rights to its late-stage small molecule anti-infectives business, primarily outside the United States.
AstraZeneca and Lilly receive FDA Fast Track designation for AZD3293, an investigational treatment for early Alzheimer's disease
- Details
- Category: AstraZeneca
AstraZeneca and Eli Lilly and Company (Lilly) today announced they have received US Food and Drug Administration (FDA) Fast Track designation for the development programme in Alzheimer's disease for AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in Phase III clinical trial.
Bayer and CRISPR Therapeutics joint venture, named Casebia Therapeutics, establishes operations in Cambridge, MA
- Details
- Category: Bayer
Casebia Therapeutics, the joint venture founded by Bayer and CRISPR Therapeutics, started its operations in Cambridge, MA, U.S. In December, 2015 Bayer and CRISPR Therapeutics agreed to create a joint venture (JV) to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease.
More Pharma News ...
- Esketamine receives Breakthrough Therapy Designation from FDA for major depressive disorder with imminent risk for suicide
- Amgen and Advaxis enter global cancer immunotherapies collaboration
- Six leading scientists to receive prestigious Novartis Prizes for Immunology at 16th International Congress of Immunology
- Pfizer announces publication of new analysis showing long-term therapy with VYNDAQEL (tafamidis) slowed progression of rare neurodegenerative disease
- Vonvendi, the first and only recombinant treatment for adults affected by von Willebrand disease, launches in the USA
- GSK and Verily to establish Galvani Bioelectronics - a new company dedicated to the development of bioelectronic medicines
- Boehringer Ingelheim: Growth in all core businesses